<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543698</url>
  </required_header>
  <id_info>
    <org_study_id>CMEK162X2110</org_study_id>
    <secondary_id>C4221005</secondary_id>
    <secondary_id>2011-005875-17</secondary_id>
    <nct_id>NCT01543698</nct_id>
  </id_info>
  <brief_title>A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, dose finding, Phase Ib dose escalation study to estimate&#xD;
      the MTD(s) and/or RP2D(s) for the dual combination of LGX818 and MEK162 and the triple&#xD;
      combination of LGX818 and MEK162 and LEE011, followed each independently by a Phase II part&#xD;
      to assess the clinical efficacy and to further assess the safety of the combinations in&#xD;
      selected patient populations. Oral LGX818 and MEK162 will be administered on a continuous&#xD;
      schedule. Oral LEE011 will be administered once daily on a three weeks on, one week off&#xD;
      schedule. Patients will be treated until progression of disease, unacceptable toxicity&#xD;
      develops, or withdrawal of informed consent, whichever occurs first. A cycle is defined as 28&#xD;
      days. The dose escalation parts of the trial will be conducted in adult patients with BRAF&#xD;
      V600-dependent advanced solid tumors and is expected to enroll at least 18 patients for the&#xD;
      dual combination and at least 12 patients for the triple combination. The dose escalation&#xD;
      will be guided by a Bayesian logistic regression model (BLRM). Following MTD/RP2D&#xD;
      declaration, patients will be enrolled in three Phase II arms for the dual combination and&#xD;
      one Phase II arm for the triple combination. All patients will be followed for 30 days for&#xD;
      safety assessments after study drugs discontinuation. All patients enrolled in the Phase II&#xD;
      part of the study will be followed for survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 2012</start_date>
  <completion_date type="Anticipated">July 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Estimation of Maximum Tolerated Dose (MTD) by measuring incidence of dose limiting toxicities (DLT)</measure>
    <time_frame>up to 8 months</time_frame>
    <description>To estimate the MTD(s) and/or recommended phase 2 dose(s) (RP2D(s)) of oral LGX818 in combination with oral MEK162, and of oral LGX818 in combination with oral MEK162 and oral LEE011 in patients with BRAF V600-dependent advanced solid tumors by measuring the incidence of DLTs as defined by the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Clinical efficacy</measure>
    <time_frame>up to 14 months</time_frame>
    <description>Assess clinical efficacy of the LGX818 and MEK162 dual combination and LGX818 and MEK162 and LEE011 triple combination in the Phase II populations by evaluating the disease control rate (DCR) and objective response rate (ORR) as per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of LGX818 and MEK162 dual combination, and LGX818 and MEK162 and LEE011 triple combination by evaluating the incidence and severity of adverse events (AE).</measure>
    <time_frame>up to 17 months</time_frame>
    <description>To characterize the safety and tolerability of LGX818 and MEK162 in combination, and LGX818 and MEK162 and LEE011 in combination by evaluating the incidence and severity (as per CTCAE grading) of AEs in all patients enrolled in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of single and multiple dose of Pharmacokinetics (PK) profile by measuring plasma concentrations versus time after study drug combination dosing (Phase Ib)</measure>
    <time_frame>up to 8 months</time_frame>
    <description>To determine the single and multiple dose PK profile of the LGX818 and MEK162 combination and LGX818 and MEK162 and LEE011 combination, by measuring plasma concentrations of MEK162 and LGX818 and LEE011 resp. at different timepoints prior and post study drug combination dosing on several days within cycle 1 and subsequent cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary clinical anti-tumor activity by evaluating the objective response rate (Phase Ib)</measure>
    <time_frame>up to 8 months</time_frame>
    <description>To assess preliminary anti-tumor activity of the LGX818 and MEK162 combination, and the LGX818 and MEK162 and LEE011 combination by evaluating the ORR as per RECIST 1.1. Safety Issue?: (FDAAA) No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further clinical efficacy (phase II)</measure>
    <time_frame>up to 14 months</time_frame>
    <description>To further assess clinical efficacy of the LGX818 and MEK162 combination and the LGX818 and MEK162 and LEE011 combination in the Phase II populations by measuring progression free survival (PFS) as per RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Solid Tumors Harboring a BRAF V600 Mutation</condition>
  <arm_group>
    <arm_group_label>dual combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LGX818 QD and MEK162 BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>triple combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LGX818 QD and MEK162 BID and LEE011 QD 3 weeks on, 1 week off.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGX818</intervention_name>
    <arm_group_label>dual combination</arm_group_label>
    <arm_group_label>triple combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162</intervention_name>
    <arm_group_label>dual combination</arm_group_label>
    <arm_group_label>triple combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <arm_group_label>triple combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically confirmed diagnosis of locally advanced or metastatic melanoma (stage IIIB&#xD;
        to IV per American Joint Committee on Cancer [AJCC]), or confirmed diagnosis of&#xD;
        non-resectable advanced metastatic colorectal cancer (mCRC), or any other indication upon&#xD;
        agreement with the Sponsor, whose disease has progressed despite previous antineoplastic&#xD;
        therapy or for whom no further effective standard therapy is available&#xD;
&#xD;
          -  Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation&#xD;
&#xD;
          -  Evidence of measurable disease as determined by RECIST v1.1&#xD;
&#xD;
          -  World Health Organization (WHO) Performance Status â‰¤ 2&#xD;
&#xD;
          -  Negative serum pregnancy test within 72 hours prior to the first study dose in all&#xD;
             women of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Progressive disease following prior treatment with RAF-inhibitors in combination with&#xD;
        MEK-inhibitors&#xD;
&#xD;
          -  Symptomatic or untreated leptomeningeal disease&#xD;
&#xD;
          -  Symptomatic brain metastases. Patients are not permitted to receive enzyme inducing&#xD;
             anti-epileptic drugs&#xD;
&#xD;
          -  Known acute or chronic pancreatitis&#xD;
&#xD;
          -  History or current evidence of retinal disease, retinal vein occlusion or&#xD;
             ophthalmopathy&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Patients with abnormal laboratory values at Screening/baseline&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of oral LGX818/MEK162&#xD;
&#xD;
          -  Previous or concurrent malignancy&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  For addition of LEE011 in the triple combination, congenital long QT syndrome or&#xD;
             family history of unexpected sudden cardiac death and/or hypokalemia CTCAE Grade â‰¥ 3,&#xD;
             brain metastases at baseline, abnormal coagulation results PT/INR &gt;1.5 x ULN or aPTT&#xD;
             &gt;1.5 x ULN.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt McKinley Outpatient Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston Inc (OCB)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis-Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione Pascale</name>
      <address>
        <city>Naples</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Monaldi</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo studio e la cura dei tumori Fondazione Giovanni Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'HebrÃ³n - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro ? CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤t ZÃ¼rich</name>
      <address>
        <city>Zurich</city>
        <state>ZÃ¼rich (DE)</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St.Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.med. Ursula Urner</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8044</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumor,</keyword>
  <keyword>BRAF V600 mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

